Clinical Report: Link Between Bisphenol Exposure and Risk of PCOS
Overview
This systematic review and meta-analysis found significant associations between bisphenol exposure and increased risk of polycystic ovary syndrome (PCOS). Specifically, elevated serum and urinary levels of bisphenol A (BPA) and bisphenol S (BPS) were linked to PCOS, highlighting the need for further research and regulatory measures.
Background
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 11-13% of women of reproductive age, associated with various metabolic and reproductive complications. Environmental endocrine-disrupting chemicals, particularly bisphenols, are suspected contributors to PCOS pathogenesis. Understanding the relationship between bisphenol exposure and PCOS is crucial for developing preventive strategies and clinical management.
Data Highlights
Exposure
Standardized Mean Difference (SMD)
95% Confidence Interval (CI)
Serum BPA
1.32
0.83–1.82
Urinary BPA
2.69
1.41–3.97
Serum BPS
0.26
0.07–0.46
Key Findings
Significant positive association between serum BPA and PCOS risk (SMD = 1.32).
Urinary BPA levels showed a stronger association with PCOS (SMD = 2.69).
Serum BPS was also positively associated with PCOS risk (SMD = 0.26).
High heterogeneity was observed for BPA studies (I² = 95–99%), while BPS studies showed no heterogeneity (I² = 0%).
Sensitivity analyses confirmed the robustness of the findings, excluding lower-quality studies.
Subgroup analyses indicated slightly attenuated associations for BPA when using Rotterdam criteria.
Clinical Implications
Clinicians should consider the potential role of bisphenol exposure in the assessment and management of PCOS. Incorporating biomonitoring for bisphenols may enhance patient care and inform preventive strategies. Regulatory measures to reduce bisphenol exposure could be beneficial for public health.
Conclusion
The findings underscore a significant association between bisphenol exposure and PCOS risk, warranting further investigation and potential regulatory action to mitigate exposure. Addressing this environmental risk factor may provide new avenues for PCOS prevention and management.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
